Mangoceuticals, Inc. Form 8-K Summary
Business Context and Reporting Period
Mangoceuticals, Inc. filed a Form 8-K under Item 8.01, Other Events, relating to its Nasdaq Capital Market listing compliance. The earliest reported event date was January 24, 2024; the filing was signed January 25, 2024. The company is an emerging growth company, and its common stock trades under the symbol MGRX.
Financial Metrics and Liquidity
- The company reported stockholders’ equity of $1,354,821 in its Form 10-Q for the quarter ended September 30, 2023.
- This amount was below Nasdaq Listing Rule 5550(b)(1)’s minimum stockholders’ equity requirement of $2.5 million.
- The company also did not meet Nasdaq’s alternative continued-listing standards.
- The filing does not provide current revenue, profitability, cash-flow, debt, cash-balance, or margin figures.
Material Changes and Nasdaq Compliance
Nasdaq notified the company on November 3, 2023 that it was not in compliance with the minimum stockholders’ equity requirement. After the company submitted a compliance plan by the December 18, 2023 deadline, Nasdaq granted an extension on January 24, 2024.
By April 29, 2024, the company must complete specified transactions contemplated by its compliance plan, which are expected to increase stockholders’ equity above $2.5 million. The company must then provide Nasdaq and the SEC with either a report describing the completed transaction and affirming compliance, or that information together with a balance sheet no older than 60 days and pro forma adjustments demonstrating compliance.
Outlook, Risks, and Contingencies
- Nasdaq will continue monitoring the company’s compliance with the stockholders’ equity requirement.
- If the company does not demonstrate compliance in its next periodic report following the compliance period, it may be subject to delisting.
- If the company fails to satisfy the extension terms, Nasdaq may issue written notice of delisting; the company would then have the right to appeal to a Nasdaq Hearings Panel.
- Management is evaluating various actions and expects the planned transactions may restore compliance, but provides no assurance that the transactions will be completed, will increase equity sufficiently, or will do so within the required period.
Investor Verification Checklist
- Verify whether the company completed the required transactions by April 29, 2024.
- Review the subsequent SEC filing and any pro forma balance sheet for evidence that stockholders’ equity exceeded $2.5 million.
- Confirm whether Nasdaq accepted the company’s evidence of compliance or issued further deficiency or delisting notices.
- Assess the financing, dilution, liquidity, and other effects of the transactions used to address the equity shortfall.
- Review subsequent periodic reports for continued compliance with Nasdaq’s listing standards.